UNSPSC 51273004: Levoxadrol

This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 811X558HU0. European Medicines Agency schedules Levoxadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08496MIG. Levoxadrol generally arises in the molecular formula C20H23NO2.

UNSPSC 51273004 Levoxadrol is a Commodity code that does not align with the recent state and local solicitations posted under it. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS therapeutic pharmacy initiative RFI, and a Minnesota multistate cooperative generic pharmaceuticals RFP—involve naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, and multi-source generic drugs and OTC products respectively. None of these procurements specifically target levoxadrol, a veterinary anesthetic agent unrelated to the opioid-response and pharmacy benefit management initiatives evident in current posting activity. The code shows little relevant recent activity under its nominal scope.

The issuing bodies span state health departments (Texas HHS), state procurement offices administering cooperative purchasing vehicles (Minnesota Department of Administration through MMCAP), and county public health functions (Seminole County, Florida). Geographically, recent tagged opportunities appear in Florida, Texas, and Minnesota, though the mismatch between the code name and actual procurement content suggests the UNSPSC categorization may not reflect how these jurisdictions are classifying their purchases. Seminole County's IFB 60459723LAS, posted June 30, 2026, solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 deadline (note the historical deadline date in the record). The Minnesota MMCAP RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, seeks generic multi-source pharmaceuticals and OTC products through authorized wholesalers for statewide and multi-state distribution. The Texas HHS RFI HHS0017013, issued April 3, 2026, explores vendor capacity for direct-to-manufacturer prescription fulfillment programs. None of these represent levoxadrol procurement.